Stock TELO TELOMIR PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Telomir Pharmaceuticals, Inc. Stock

Equities

TELO

US87975F1049

Pharmaceuticals

Real-time Estimate Cboe BZX
Other stock markets
 11:43:16 2024-05-30 am EDT 		5-day change 1st Jan Change
6.055 USD -5.83% Intraday chart for Telomir Pharmaceuticals, Inc. -4.29% 0.00%
May. 13 Telomir Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 16 Telomir Pharmaceuticals, Inc. Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C CI

Financials (USD)

Sales 2022 - Sales 2023 - Capitalization 190M
Net income 2022 - Net income 2023 -13M EV / Sales 2022 * -
Net cash position 2022 * - Net cash position 2023 * - EV / Sales 2023 * -
P/E ratio 2022 *
-
P/E ratio 2023 *
-
Employees 5
Yield 2022 *
-
Yield 2023 *
-
Free-Float 57.52%
More Fundamentals * Assessed data

Chart Telomir Pharmaceuticals, Inc.

Dynamic Chart

Latest news about Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Telomir Pharmaceuticals, Inc. Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C CI
Telomir Pharmaceuticals, Inc. Announces Resignation of Christos Nicholoudis, Esq. as the General Counsel and A Member of the Board of Directors CI
Telomir Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines CI
Telomir Pharmaceuticals Presents Promising Pre-Clinical Data for Its Lead Development Product At Singapore Conference CI
Telomir Pharmaceuticals, Inc.(NasdaqCM:TELO) added to NASDAQ Composite Index CI
Telomir Pharmaceuticals, Inc. has completed an IPO in the amount of $7 million. CI
More news

Press releases Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1 AQ
Telomir Pharmaceuticals, Inc. Signs Media Deal with New to The Street for Network Interview Broadcasts, Billboards, and TV Commercial Support AQ
Telomir Pharmaceuticals sees breakthrough potential in Anti-Aging Treatment with Telomir 1 AQ
Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C. AQ
Telomir Pharmaceuticals’ Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024 AQ
More press releases

Quotes and Performance

1 day+3.21%
1 week+14.82%
Current month-2.87%
1 month-11.56%
3 months-29.11%
More quotes

Highs and lows

1 week
6.00
Extreme 6
7.19
1 month
5.56
Extreme 5.56
7.40
Current year
4.76
Extreme 4.76
20.72
1 year
4.76
Extreme 4.76
20.72
3 years
4.76
Extreme 4.76
20.72
5 years
4.76
Extreme 4.76
20.72
10 years
4.76
Extreme 4.76
20.72
More quotes

Managers and Directors - Telomir Pharmaceuticals, Inc.

Managers TitleAgeSince
Christopher Chapman CEO
 Chief Executive Officer 71 21-08-25
Nathen Fuentes DFI
 Director of Finance/CFO 41 23-09-20
Michelle Yanez AUD
 Comptroller/Controller/Auditor 52 22-04-30
Members of the board TitleAgeSince
Christopher Chapman CEO
 Chief Executive Officer 71 21-08-25
Craig Eagle BRD
 Director/Board Member 57 22-10-31
Talhia Tuck BRD
 Director/Board Member 46 22-10-31
More insiders

Company Profile

Telomir Pharmaceuticals, Inc. is a United States-based company. The Company operates as pre-clinical-stage pharmaceutical company focused on developing TELOMIR-1 small molecule to lengthen the deoxyribonucleic acid’s (DNA) protective telomere caps to affect age reversal. It selectively affects the processes that drive the concentration and accumulation of iron and copper in the serum that affects diseases like hemochromatosis and cancer.
Sector
Pharmaceuticals
More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

1st Jan change Capi.
TELOMIR PHARMACEUTICALS, INC. Stock Telomir Pharmaceuticals, Inc.
0.00% 190M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+39.22% 731B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.39% 586B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.85% 348B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.48% 319B
ABBVIE INC. Stock AbbVie Inc.
-0.12% 273B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.57% 235B
ROCHE HOLDING AG Stock Roche Holding AG
-7.16% 203B
NOVARTIS AG Stock Novartis AG
+7.23% 202B
AMGEN INC. Stock Amgen Inc.
+2.93% 159B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. TELO Stock